A lifestyle science firm that develops ultrasensitive proteins analysis technology.

Lysates from multiple unstimulated tumor cell lines had been weighed against those from the same cell lines particularly stimulated with ligands to many well-known surface area receptors for expressed adjustments in their phosphorylation claims. The outcomes indicated that the AMMP assays identify a variety of phosphoproteins with improved sensitivity with easier workflow. Correlation between proteins concentration and cell quantities determined that far less than 1000 cells had been needed per evaluation which is essential when assaying tumor biopsy samples where in fact the cell amounts collected are usually low.The IND submitting is an important milestone for all of us, as it completes our pre-clinical stage of transitions and development Circadian right into a clinical development company. We expect to commence our first in man Phase I studies as soon as possible after FDA review. We also expect to see results from the scholarly research in the next half of 2012, stated Robert Klupacs, CEO of Circadian Systems Limited. Circadian’s wholly owned subsidiary, Vegenics Pty Ltd, owns worldwide rights to a thorough intellectual property portfolio covering the lymphangiogenesis and angiogenesis targets VEGF-C, VEGF-D and the receptor protein VEGFR-3..